Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Acamprosate
Drug ID BADD_D00016
Description Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending.[A229073] Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. It is a structural analogue of the neurotransmitter γ-aminobutyric acid (GABA).[L31758] Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification[A997], unlike [naltrexone] and [disulfiram]. It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]
Indications and Usage Acamprosate is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. It is also indicated for the maintenance of alcohol abstinence in patients who have undergone alcohol detoxification. This drug should be used with a psychosocial support program providing adequate support.[L31738]
Marketing Status approved; investigational
ATC Code N07BB03
DrugBank ID DB00659
KEGG ID D07058
MeSH ID D000077443
PubChem ID 71158
TTD Drug ID D0GC2M
NDC Product Code Not Available
UNII N4K14YGM3J
Synonyms Acamprosate | Acamprostate | N-Acetylhomotaurine | N Acetylhomotaurine | Campral EC | N-Acetylhomotaurine, Magnesium (2:1) Salt | N-Acetylhomotaurine, Monolithium Salt | N Acetylhomotaurine, Monolithium Salt | N-Acetylhomotaurine, Zinc (2:1) Salt | Campral | N-Acetylhomotaurine, Monosodium Salt | N Acetylhomotaurine, Monosodium Salt | Sodium Acetylhomotaurine | Acetylhomotaurine, Sodium | Zulex | Acamprosate Calcium | Calcium Acetylhomotaurine | Acetylhomotaurine, Calcium | Calcium Acetylhomotaurinate | Acetylhomotaurinate, Calcium | N-Acetylhomotaurine, Calcium (2:1) Salt | Calcium Acetyl Homotaurinate | Acetyl Homotaurinate, Calcium | N-Acetylhomotaurine, Monopotassium Salt | N Acetylhomotaurine, Monopotassium Salt | Aotal | Regtect
Chemical Information
Molecular Formula C5H11NO4S
CAS Registry Number 77337-76-9
SMILES CC(=O)NCCCS(=O)(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Muscle twitching15.05.03.005--Not Available
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myopathy15.05.05.001--Not Available
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nephrolithiasis20.04.01.002--
Nervousness19.06.02.003--Not Available
Neuralgia17.02.07.005--
Neurosis19.06.01.001--Not Available
Nocturia20.02.03.001--Not Available
Oedema peripheral08.01.07.007; 14.05.06.011; 02.05.04.007--
Oesophagitis07.08.05.001--
Orthostatic hypotension24.06.03.004; 17.05.01.020--Not Available
Pain08.01.08.004--
Palpitations02.11.04.012--
Pancreatitis07.18.01.001--
Panophthalmitis06.04.05.005--Not Available
Paraesthesia23.03.03.094; 17.02.06.005--
Paranoia19.05.01.005--Not Available
Pharyngitis11.01.13.003; 07.05.07.004; 22.07.03.004--
Phlebitis24.12.03.004; 12.02.01.002--
Photophobia17.17.02.006; 06.01.01.004--
Photosensitivity reaction23.03.09.003--
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pollakiuria20.02.02.007--
Polyuria20.02.03.002--Not Available
Pruritus23.03.12.001--
Psoriasis23.03.14.002; 10.02.01.036--Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages